Semin Liver Dis 2005; 25(3): 327-336
DOI: 10.1055/s-2005-916324
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Etiology of Primary Biliary Cirrhosis: The Search for the Culprit

Patrick S.C Leung1 , Ross L. Coppel2 , M. Eric Gershwin1 , 3
  • 1Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis School of Medicine, Genomic and Biomedical Sciences Facility, Davis California
  • 2Department of Microbiology, Monash University, Melbourne, Australia
  • 3Chief, Division of Rheumatology, Allergy and Clinical Immunology
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
06. September 2005 (online)

Preview

ABSTRACT

Primary biliary cirrhosis (PBC) is an organ-specific autoimmune disease characterized by the presence of high titer antimitochondrial autoantibodies (AMAs) and destruction of intrahepatic small bile ducts. Despite vigorous efforts in the characterization of autoantibodies and bile duct histopathology, the etiology of this disease is unclear. Although there is no correlation between the titer of AMAs and disease severity, the presence of AMAs usually occurs before symptoms of liver abnormalities. We believe that the production of AMAs is not an epiphenomenon, and an understanding of the mechanism of AMA induction will shed light on the etiology of PBC. Recent studies have suggested that the induction of PBC is multifactorial, in which the primary player involves the xenobiotics modification of mitochondrial proteins or exposure to xenobiotic-modified bacterial mitochondrial protein homologs, leading to breaking of tolerance to the human mitochondrial autoantigens and eventually liver pathology in genetic susceptible individuals. We discuss the immunophysiological characteristics of biliary epithelial cells, biochemistry of the 2-oxo-acid dehydrogenase complex, and environmental and genetic factors relevant to PBC.

REFERENCES

M. Eric GershwinM.D. 

Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis School of Medicine

451 E. Health Sciences Drive, Suite 6510

Davis, CA 95616

eMail: megershwin@ucdavis.edu